Insulin resistance and metabolic profile in lean and overweight/obese polycystic ovary syndrome patients;Resistência insulínica e perfil metabólico em pacientes com síndrome dos ovários policísticos de peso normal e sobrepeso/obesidade

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 50, Issue 6, 2006, Pages 1026-1033

  Kuba, Valesca Mansur ^a,b   Cavalieri, Patricia M ^a   Christóforo, Ângela Casillo ^a   Faria Jr , Raul ^a   Caetano, Rosângela ^a   Coeli, Cláudia Medina ^a   Athayde, Amanda ^a  

^a Instituto Estadual de Diabetes e Endocrinologia Luiz Capriglione   (Brazil)

^b NONE   (United States)

Author keywords

Insulin resistance; Metabolic syndrome; Obesity; Polycystic ovary syndrome

Indexed keywords

INSULIN; LIPID;

ADOLESCENT; ADULT; ARTICLE; BLOOD; BLOOD PRESSURE; BODY MASS; CROSS-SECTIONAL STUDY; DYSLIPIDEMIA; FEMALE; GLUCOSE TOLERANCE TEST; HUMAN; INSULIN RESISTANCE; LIPID METABOLISM; METABOLISM; MIDDLE AGED; NONPARAMETRIC TEST; OBESITY; OVARY POLYCYSTIC DISEASE; PHYSIOLOGY; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; BLOOD PRESSURE; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; DYSLIPIDEMIAS; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; INSULIN RESISTANCE; LIPID METABOLISM; LIPIDS; MIDDLE AGED; OBESITY; POLYCYSTIC OVARY SYNDROME; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC;

EID: 33846389251     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/S0004-27302006000600008     Document Type: Article

References (48)

1. Taylor AE. Polycystic ovary syndrome. Endocrinol Metab Clin North Am 1998;27(4):877-902.
2. Ehrmann DA, Rosenfield RL, Barnes RB, Brigell DF, Sheikh Z. Detection of functional ovarian hyperandrogenism in women with androgen excess. N Engl J Med 1992;327:157-62.
3. Amowitz LL, Sobel B. Cardiovascular consequences of polycystic ovary syndrome. Endocrinol Metab Clin North Am 1999;28(2):439-58.
4. Dunaif A. Insulin action in the polycystic ovary syndrome. Endocrinol Metab Clin North Am 1999;28(2):341-57.
5. Morales AJ, Laughlin GA, Butzow T, Maheshwari H, Baumann G, Yen SSC, et al. Insulin, somatotropic and luteinizing hormone axes in lean and obese women with polycyistic ovary syndrome: Common and distinct features. J Clin Endocrinol Metab 1996;81(8):2854-64.
6. Legro RS, Finegood D, Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1998;83(8):2694-8.
7. Ibanez L, Valls C, Ferrer A, Ong K, Dunger DB, DeZegher E. Additive effects of insulin-sensitizing and anti-androgen treatment in young, nonobese women with hyperinsulinism, hyperandrogenism, dyslipidemia, and anovulation. J Clin Endocrinol Metab 2002;87(6):2870-4.
8. Yildiz BO, Yarali H, Oguz H, Bayraktar M. Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88(5):2031-6.
9. Ünlühizarci K, Karababa Y, Bayram F, Kelestimur FI. The investigation of insulin resistance in patients with idiopathic hirsutism. J Clin Endocrinol Metab 2004;89(6):1-7.
10. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440-6.
11. Malloy MJ, Kane JP. Disorders of lipoprotein metabolism. In: Greenspan FS, Gardner DG. Basical & Clinical Endocrinology. USA: Lange, 2001. cap. 20, p. 716-44.
12. Expert Commitee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Commitee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20(7):1183-97.
13. Matthews DR, Hosker JP, Rudenski AS, Naylor BA. Homeostasis model assessment insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
14. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
15. Nestler JE, Jakubowicz DJ. Lean woman with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17α activity and serum androgens. J Clin Endocrinol Metab 1997;82(12):4075-9.
16. Hayashida SAY, Halbe HW, Marcondes JAM, Normando APC, Lopes CMC, Gonçalves MA, et al. Comparação entre diferentes índices de avaliação da sensibilidade à insulina na síndrome dos ovários policísticos. Rev Ginecol Obstet 2004;15(2):69-77.
17. Vendrell J, Broch M, Vilarrasa N, Molina A, Gomez JM, Gutierrez C, et al. Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity. Obes Res 2004;12:962-71.
18. Sopasakis VR, Sandquit M, Gustafsom B, Hammarstedt A, Schmelz M, Yang X, et al. High local concentrations and effects on differentiation implicate interleukin-6 as a paracrine regulator. Obes Res 2004;12:454-60.
19. Dunaif A, Wu X, Lee A, Diamanti-Kandarakis E. Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS). AJP-Endocrinol Metab 2001;281:392-9.
20. The IDF consensus worldwide definition of the metabolic syndrome. Available at: 〈http://www.idf.org/home/index.cfm?node=1429〉. Acessed in: 7 aug. 2005.
21. Reaven G. Syndrome X 10 years after. Drugs 1999;58(Suppl 1):19-20.
22. The Rotterdam ESHRE/ASRM Sponsored PCOS Consensus Workshop Group 2004. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81(1):19-25.
23. Boots LR, Potter S, Potter HD, Azziz R. Measurement of total serum testosterone levels using commercially available kits: high degree of between-kit variability. Fertil Steril 1998;69(2):286-92.
24. Rosner W. Errors in the measurement of plasma free testosterone. J Clin Endocrinol Metab 1997;82(6):2014-5.
25. Gluek CL, Papanna R, Wang P, Goldenberg N, Sieve-Smith L. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism 2003;53(7).
26. Vermeulen A, Verdonk L, Kaufman J. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999;84(10):3666-72.
27. Ehrmann, DA. Polycystic ovary syndrome. N Engl J Med 2005;352:1223-36.
28. Pelusi C, Pasquali R. Polycystic ovary syndrome in adolescents: Pathophysiology and treatment implications. Treat Endocrinol 2003;2(4):215-30.
29. Goodarzi MO, Erickson S, Port SC, Jennrich RI, Korenman SG. β-Cell function: A key pathological determinant in polycystic ovary syndrome. J Clin Endocrinol Metab 2004;90(1):310-5.
30. Vrbíková J, Cibula D, Dvorárová K, Stanickás S, Sindelka G, Hill M, et al. Insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89(6):2942-5.
31. Vrbíková J, Bendlová B, Hill M, Vanková M, Vondra K, Stárka L. Insulin sensitivity and ß-cell function in women with polycystic ovary syndrome. Diabetes Care 2002;25(7):1217-22.
32. Chang WY, Knochenhauer ES, Bartolucci AA, Azziz R. Phenotypic spectrum of polycystic ovary syndrome: clinical and biochemical characterization of the three major clinical subgroups. Fertil Steril 2005;83(6):1717-23.
33. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999;22(1):141-5.
34. Ehermann DA, Kasza K, Azziz R, Legro RS, Ghazzi MN. Effects of race and family history of type 2 diabetes on metabolic status of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90(1):66-71.
35. Legro RS, Kulselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome. J Clin Endocrinol Metab 1999;84(1):165-9.
36. Dunaif A, Finegood DT. β-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996;81(3):942-7.
37. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistence, independent of obesity, in polycystic ovary syndrome. Diabetes 1989;38:1165-74.
38. American Association of Clinical Endocrinologists position statement on metabolic and cardiocascular consequences of polycystic ovary syndrome. Endocr Pract 2005;11(2):125-34.
39. Solomon CG, Lu FB, Dunaif A, Eduards JR, Willet WC, Hunter DI, et al. Long or highly irregular menstrual cycles as a marker for risk of type 2 Diabetes Mellitus. JAMA 2001;286:2421-6.
40. Palmert MR, Gordon CM, Kartashov AI, Legro RS, Emans SJ, Dunaif A. Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;87(3):1017-23.
41. Wild RA. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1985;61(5):946-51.
42. Rajkhowa M, Neary RH, Kumpatla P, Game FL, Jones PW, Obhrai MS, et al. Altered composition of high-density lipoproteins in women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1997;82(10):3389-94.
43. Kwiterovich PO. The metabolic pathways of high-density lipoprotein, low-density lipoprotein, and triglycerides: A current review. Am J Cardiol 2000;86(suppl):5L-10L.
44. Boulman N, Levy Y, Leiba R, Shachar S, Linn R, Zinder O, et al. Increased C-reative protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metab 2004;89(5):2160-5.
45. Paradisi G, Steinberg HO, Hepard MK, Hook G, Baron AD. Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88(2):576-80.
46. Premoli ACG, Moura MD, Ferriani RA, Sá MFS, Reis RM. Perfil lipídico em pacientes portadoras da síndrome dos ovários policísticos. RBGO 2000;22(2):89-94.
47. Haber EP, Curi R, Carvalho CRO, Carpineli AR. Secreção da insulina: Efeito autócrino da insulina e modulação por ácidos graxos. Arq Bras Endocrinol Metab 2001;45(3):219-27.
48. Diamanti-Kandarakis E, Kouli C, Alexandraki K, Spina G. Failure of mathematical indices to accurately assess insulin resistense in lean, overweight, or obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89(3):1273-6.